No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3

M. Wiese, F. Schill, D. Sturm, S. Pfister, E. Hulleman, S. A. Johnsen, C. M. Kramm

Research output: Contribution to journalArticleAcademicpeer-review

44 Citations (Scopus)
Original languageEnglish
Pages (from-to)113-117
JournalKlinische Pädiatrie
Volume228
Issue number3
DOIs
Publication statusPublished - May 2016

Keywords

  • EZH2 inhibition
  • Tazemetostat (EPZ-6438)
  • cancer epigenetics
  • histone 3 mutation
  • pediatric high-grade glioma (pedHGG)

Cite this